이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Shanghai Haohai Biological Technology 관리
관리 기준 확인 4/4
Shanghai Haohai Biological Technology's CEO는 Jianying Wu, Jul2010 에 임명되었습니다 의 임기는 13.92 년입니다. 총 연간 보상은 CN¥ 1.90M, 44.9% 로 구성됩니다. 44.9% 급여 및 55.1% 보너스(회사 주식 및 옵션 포함). 는 HK$ 675.90M 가치에 해당하는 회사 주식의 3.37% 직접 소유합니다. 675.90M. 경영진과 이사회의 평균 재임 기간은 각각 9.5 년과 10.6 년입니다.
주요 정보
Jianying Wu
최고 경영자
CN¥1.9m
총 보상
| CEO 급여 비율 | 44.9% |
| CEO 임기 | 13.9yrs |
| CEO 소유권 | 3.6% |
| 경영진 평균 재임 기간 | 9.5yrs |
| 이사회 평균 재임 기간 | 10.6yrs |
최근 관리 업데이트
Recent updates
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Can Mixed Fundamentals Have A Negative Impact on Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Current Share Price Momentum?
Feb 23What Type Of Shareholders Own The Most Number of Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Shares?
Feb 05
Does Shanghai Haohai Biological Technology's (HKG:6826) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 21Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Should Think About This Before Buying It For Its Dividend
Jan 06CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥432m |
| Dec 31 2023 | CN¥2m | n/a | CN¥416m |
| Sep 30 2023 | n/a | n/a | CN¥346m |
| Jun 30 2023 | n/a | n/a | CN¥315m |
| Mar 31 2023 | n/a | n/a | CN¥226m |
| Dec 31 2022 | CN¥2m | CN¥855k | CN¥180m |
| Sep 30 2022 | n/a | n/a | CN¥203m |
| Jun 30 2022 | n/a | n/a | CN¥192m |
| Mar 31 2022 | n/a | n/a | CN¥272m |
| Dec 31 2021 | CN¥1m | CN¥845k | CN¥352m |
| Sep 30 2021 | n/a | n/a | CN¥428m |
| Jun 30 2021 | n/a | n/a | CN¥434m |
| Mar 31 2021 | n/a | n/a | CN¥370m |
| Dec 31 2020 | CN¥1m | CN¥768k | CN¥230m |
| Sep 30 2020 | n/a | n/a | CN¥232m |
| Jun 30 2020 | n/a | n/a | CN¥216m |
| Mar 31 2020 | n/a | n/a | CN¥279m |
| Dec 31 2019 | CN¥2m | CN¥742k | CN¥371m |
| Sep 30 2019 | n/a | n/a | CN¥353m |
| Jun 30 2019 | n/a | n/a | CN¥386m |
| Mar 31 2019 | n/a | n/a | CN¥375m |
| Dec 31 2018 | CN¥1m | CN¥712k | CN¥415m |
| Sep 30 2018 | n/a | n/a | CN¥411m |
| Jun 30 2018 | n/a | n/a | CN¥408m |
| Mar 31 2018 | n/a | n/a | CN¥390m |
| Dec 31 2017 | CN¥1m | CN¥583k | CN¥372m |
보상 대 시장: Jianying 의 총 보상 ($USD 262.37K ) Hong Kong 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 452.40K ).
보상과 수익: Jianying 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Jianying Wu (60 yo)
13.9yrs
테뉴어
CN¥1,904,800
보상
Dr. Jianying Wu has been General Manager of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010 and has been its Executive Director since December 2014. Mr. Wu served as a Director at Shang...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 13.9yrs | CN¥1.89m | 3.58% CN¥ 506.1m | |
| GM & Executive Director | 13.9yrs | CN¥1.90m | 3.61% CN¥ 511.4m | |
| CFO & Executive Director | 7.5yrs | CN¥1.45m | 0.036% CN¥ 5.0m | |
| Executive Director | 9.5yrs | CN¥1.26m | 0.25% CN¥ 35.8m | |
| Joint Company Secretary | 4.5yrs | CN¥868.70k | 0.0043% CN¥ 612.6k | |
| Deputy General Manager | 9.8yrs | CN¥912.50k | 0.012% CN¥ 1.6m | |
| Joint Company Secretary | 9.6yrs | 데이터 없음 | 데이터 없음 |
9.5yrs
평균 재임 기간
49yo
평균 연령
경험이 풍부한 관리: 6826 의 관리팀은 노련하고 경험 (평균 재직 기간 9.5 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 13.9yrs | CN¥1.89m | 3.58% CN¥ 506.1m | |
| GM & Executive Director | 13.9yrs | CN¥1.90m | 3.61% CN¥ 511.4m | |
| CFO & Executive Director | 7.3yrs | CN¥1.45m | 0.036% CN¥ 5.0m | |
| Executive Director | 13.9yrs | CN¥1.26m | 0.25% CN¥ 35.8m | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Non Executive Director | 13.9yrs | 데이터 없음 | 46.45% CN¥ 6.6b | |
| Non-Executive Director | 13.9yrs | CN¥150.00k | 1.19% CN¥ 168.5m | |
| Chairman of the Supervisory Committee | 13.9yrs | 데이터 없음 | 1.19% CN¥ 168.5m | |
| Independent Non-Executive Director | 4yrs | CN¥150.00k | 데이터 없음 | |
| Independent Non-Executive Director | 4yrs | CN¥150.00k | 데이터 없음 | |
| Independent Non-Executive Director | 4yrs | CN¥150.00k | 데이터 없음 | |
| Independent Non-Executive Director | 4yrs | CN¥150.00k | 데이터 없음 |
10.6yrs
평균 재임 기간
52.5yo
평균 연령
경험이 풍부한 이사회: 6826 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.6 년).